MX2021006503A - Métodos para la expansión in vivo selectiva de poblaciones de células t gamma delta y composiciones de estas. - Google Patents
Métodos para la expansión in vivo selectiva de poblaciones de células t gamma delta y composiciones de estas.Info
- Publication number
- MX2021006503A MX2021006503A MX2021006503A MX2021006503A MX2021006503A MX 2021006503 A MX2021006503 A MX 2021006503A MX 2021006503 A MX2021006503 A MX 2021006503A MX 2021006503 A MX2021006503 A MX 2021006503A MX 2021006503 A MX2021006503 A MX 2021006503A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- selective
- cell populations
- vivo expansion
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000001727 in vivo Methods 0.000 title abstract 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 title 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a métodos para la activación, expansión y/o mantenimiento in vivo selectiva de la o las poblaciones de células T ?d, composiciones y mezclas de estas y métodos para su uso como una terapia. Los métodos y composiciones de la descripción son útiles en el tratamiento de diversos cánceres, enfermedades infecciosas y trastornos autoinmunes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862774817P | 2018-12-03 | 2018-12-03 | |
PCT/US2019/064319 WO2020117862A1 (en) | 2018-12-03 | 2019-12-03 | Methods for selective in vivo expansion of gamma delta t-cell populations and compositions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021006503A true MX2021006503A (es) | 2021-08-05 |
Family
ID=69005987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021006503A MX2021006503A (es) | 2018-12-03 | 2019-12-03 | Métodos para la expansión in vivo selectiva de poblaciones de células t gamma delta y composiciones de estas. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220218747A1 (es) |
EP (1) | EP3890757A1 (es) |
JP (1) | JP2022510387A (es) |
KR (1) | KR20210099615A (es) |
CN (1) | CN113518624A (es) |
AU (1) | AU2019394877A1 (es) |
BR (1) | BR112021010804A2 (es) |
CA (1) | CA3126896A1 (es) |
IL (1) | IL283614A (es) |
MX (1) | MX2021006503A (es) |
SG (1) | SG11202105860QA (es) |
WO (1) | WO2020117862A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022006547A (es) * | 2019-12-03 | 2022-08-19 | Adicet Bio Inc | Métodos para la expansión de poblaciones de células t gamma delta con agentes multivalentes y composiciones de estas. |
WO2022109477A1 (en) * | 2020-11-23 | 2022-05-27 | University Of Florida Research Foundation, Incorporated | Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0633943A4 (en) | 1992-04-03 | 1997-05-02 | Alexander T Young | GENTHERAPY USING TARGETED VIRAL VECTORS. |
AU2003251286B2 (en) | 2002-01-23 | 2007-08-16 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
US7985739B2 (en) | 2003-06-04 | 2011-07-26 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced sleeping beauty transposon system and methods for using the same |
MX336846B (es) | 2010-01-22 | 2016-02-03 | Sangamo Biosciences Inc | Alteracion genomica dirigida. |
MY160662A (en) | 2011-04-01 | 2017-03-15 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 |
EP2684600A1 (en) | 2012-07-10 | 2014-01-15 | Laboratoires Meiners Sarl | Core-shell capsules and methods for encapsulation of reactive ingredients by diffusional exchange through spherical capsule membranes |
WO2014072446A1 (en) * | 2012-11-08 | 2014-05-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for inducing il-2-free proliferation of gamma delta t cells |
WO2014134412A1 (en) | 2013-03-01 | 2014-09-04 | Regents Of The University Of Minnesota | Talen-based gene correction |
CN104651308A (zh) * | 2013-11-22 | 2015-05-27 | 深圳先进技术研究院 | 一种用磷酸盐扩增γδT细胞的方法及其应用 |
RU2756247C2 (ru) | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
WO2017197347A1 (en) * | 2016-05-12 | 2017-11-16 | Adicet Bio, Inc. | METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF |
SG11202004506WA (en) | 2017-11-15 | 2020-06-29 | Adicet Bio Inc | METHODS FOR SELECTIVE EXPANSION OF d3 ?d T-CELL POPULATIONS AND COMPOSITIONS THEREOF |
-
2019
- 2019-12-03 BR BR112021010804A patent/BR112021010804A2/pt unknown
- 2019-12-03 KR KR1020217020436A patent/KR20210099615A/ko unknown
- 2019-12-03 SG SG11202105860QA patent/SG11202105860QA/en unknown
- 2019-12-03 AU AU2019394877A patent/AU2019394877A1/en active Pending
- 2019-12-03 MX MX2021006503A patent/MX2021006503A/es unknown
- 2019-12-03 EP EP19828054.7A patent/EP3890757A1/en active Pending
- 2019-12-03 CN CN201980087911.3A patent/CN113518624A/zh active Pending
- 2019-12-03 JP JP2021531558A patent/JP2022510387A/ja active Pending
- 2019-12-03 CA CA3126896A patent/CA3126896A1/en active Pending
- 2019-12-03 US US17/298,903 patent/US20220218747A1/en active Pending
- 2019-12-03 WO PCT/US2019/064319 patent/WO2020117862A1/en unknown
-
2021
- 2021-06-01 IL IL283614A patent/IL283614A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220218747A1 (en) | 2022-07-14 |
WO2020117862A1 (en) | 2020-06-11 |
IL283614A (en) | 2021-07-29 |
CA3126896A1 (en) | 2020-06-11 |
EP3890757A1 (en) | 2021-10-13 |
JP2022510387A (ja) | 2022-01-26 |
KR20210099615A (ko) | 2021-08-12 |
BR112021010804A2 (pt) | 2021-11-16 |
AU2019394877A1 (en) | 2021-06-17 |
CN113518624A (zh) | 2021-10-19 |
SG11202105860QA (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023006546A (es) | Metodos para la expansion selectiva de poblaciones de celulas t gama y composiciones de estas. | |
PH12020500396A1 (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof | |
PH12020500241A1 (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
MX2023014569A (es) | Anticuerpos anti-sirpa. | |
MX2017006408A (es) | Linfocitos t gamma delta modificados geneticamente. | |
MX2019014974A (es) | Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson. | |
MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
EP4310500A3 (en) | Methods and compositons for the activation of gamma-delta t-cells | |
EA201791999A1 (ru) | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" | |
MX2019014122A (es) | Formulaciones de dosis fija. | |
MX2022002740A (es) | Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes. | |
PH12020551251A1 (en) | Jak1 pathway inhibitors for the treatment of cytokine-related disorders | |
MX2019012144A (es) | Arn para tratamiento de enfermedades autoinmunitarias. | |
PH12019500643A1 (en) | Antibodies that bind interleukin-2 and uses thereof | |
PH12021550872A1 (en) | Therapeutic compounds | |
CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
MX2022006817A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
MX2021006503A (es) | Métodos para la expansión in vivo selectiva de poblaciones de células t gamma delta y composiciones de estas. | |
MX2021005248A (es) | Anticuerpos contra cd73 activadores de células b. | |
MX2017013564A (es) | Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual. | |
MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
WO2020180712A8 (en) | Anti-tnfr2 antibodies and uses thereof | |
MX2022006547A (es) | Métodos para la expansión de poblaciones de células t gamma delta con agentes multivalentes y composiciones de estas. | |
MX2022010674A (es) | Población de linfocitos y métodos para producirla. |